Biotek-snakken — December 2023
-
Kort video: Den mest omtalte aktie gennem tiden på ProInvestor.com er Genmab. Herefter kommer Anavex, som lige nu venter på en tilbagemelding fra de europæiske lægemiddelmyndigheder om deres stof i relation til Alzheimers. En anden populær aktie er Zealand Pharma, som i sidste uge holdt en event i London - på mandag tager Helge Larsen ud til virksomheden og taler med CEO Adam Steensberg om hovedpointerne fra eventen. Stay tuned. https://www.proinvestor.com/boards/117109
-
-
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years https://www.globenewswire.com/en/news-release/2023/12/07/2792907/0/en/BioPorto-Receives-FDA-510-k-Clearance-for-NGAL-Test-in-the-United-States-First-Test-to-Aid-in-Assessing-AKI-Risk-for-Patients-Aged-3-Months-Through-21-Years.html?fbclid=IwAR1wGlv48EeIHXNM8AePhUyPugdRYWXpz3BC4brJFwGoMka9YbrducsCD80
-
Bioporto sikrer sig afgørende FDA-godkendelse til nyretest https://www.proinvestor.com/investornyt/1087842/bioporto-sikrer-sig-afgorende-fda-godkendelse-til-nyretest
-
Godmorgen
-
Astellas' Veoza Approved In Europe For Treatment Of Vasomotor Symptoms Associated With Menopause https://www.proinvestor.com/investornyt/1088746/astellas-veoza-approved-in-europe-for-treatment-of-vasomotor-symptoms-associated-with-menopause
-
Genentech : Longer-term Data From Studies Of Columvi & Lunsumio Show Durable Responses In Lymphomas https://www.proinvestor.com/investornyt/1088754/genentech-longer-term-data-from-studies-of-columvi-amp-lunsumio-show-durable-responses-in-lymphomas
-
Sanofi Terminates Pompe Disease Drug Agreement With Maze Therapeutics Following FTC Opposition https://www.proinvestor.com/investornyt/1089315/sanofi-terminates-pompe-disease-drug-agreement-with-maze-therapeutics-following-ftc-opposition
-
Kort video - Der sket meget med de aktier, som er mest populære på ProInvestor.com. Først er det den ene vej, og nu er det så den anden vej. Zealand Pharma er kommet i C25, hvilket gav udslag i kursen - først op, så ned, så op igen. Genmab er igen det mest omtalte selskab, bl.a. efter positive resultater på deres studie med epcoritamab. Kursen var dog alligevel nede og vende pga. resultaterne i et andet af deres studier. Bioporto og Ngal. https://www.proinvestor.com/boards/117281
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind